Botulinum toxin for chronic anal fissure after biliopancreatic diversion for morbid obesity

Table 4 Univariate analysis of parameters registered 1 and 2 mo after treatment

Risk factor	P value1	P value2
Age	0.4275	0.4034
Sex	0.1147	0.4128
Duration of symptoms	0.4566	0.4018
Post-defecatory anal pain	0.6889	NA
Nocturnal anal pain	0.1008	0.1039
Anal pain unrelated to defecation	0.1507	0.1039
Bleeding	0.4669	0.1585
Mucorrhea	0.5826	0.2081
Other anal pathologies	0.1656	0.1591
Extra-anal associated pathologies	0.3223	0.133
Defecation pattern	0.3825	0.3972
Stool consistency	0.3825	0.3291
Number of evacuations/wk	0.1656	0.4197
Straining	0.2244	0.2615
Sensation of incomplete evacuation	0.2244	0.7323
Laxative use	0.2244	0.2615
Enemas/ suppositories use	0.2244	0.7323
Botulinum toxin dose	0.8151	0.1635
Resting anal tone	0.6889	NA
Maximal voluntary anal squeeze	0.2094	0.6179
Puborectal muscle relaxation	0.3111	NA
MVAS 0 (mmHg)	0.2457	0.7281
MVAS 1 (mmHg)	0.5292	0.4133
MVAS 2	NA	0.8272
RAP 0 (mmHg)	0.284	0.1322
RAP 1 (mmHg)	0.3513	0.0985
RAP 2	NA	0.172
Site of injection	0.0818	0.5815

MVAS 0: Maximal voluntary anal squeeze (pretreatment); MVAS 1: Maximal voluntary anal squeeze (1 mo after the treatment); MVAS 2: Maximal voluntary anal squeeze (2 mo after the treatment); RAP 0: Resting anal pressure (pretreatment); RAP 1: Resting anal pressure (1 mo after treatment); RAP 2: Resting anal pressure (2 mo after treatment). NA: Not applicable. 1: 1 mo after treatment; 2: 2 mo after treatment.